BR112019004189A2 - trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos - Google Patents

trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos

Info

Publication number
BR112019004189A2
BR112019004189A2 BR112019004189-3A BR112019004189A BR112019004189A2 BR 112019004189 A2 BR112019004189 A2 BR 112019004189A2 BR 112019004189 A BR112019004189 A BR 112019004189A BR 112019004189 A2 BR112019004189 A2 BR 112019004189A2
Authority
BR
Brazil
Prior art keywords
virus group
nanoparticles
influenza
influenza virus
fusion proteins
Prior art date
Application number
BR112019004189-3A
Other languages
English (en)
Portuguese (pt)
Inventor
C. Boyington Jeffrey
S. Graham Barney
R. Mascola John
M. Yassine Hadi
S. Corbett Kizzmekia
M. Moin Syed
Wang Lingshu
Kanekiyo Masaru
Original Assignee
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Usa, As Represented By The Secretary, Dept. Of Health And Human Services filed Critical The Usa, As Represented By The Secretary, Dept. Of Health And Human Services
Publication of BR112019004189A2 publication Critical patent/BR112019004189A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nanotechnology (AREA)
BR112019004189-3A 2016-09-02 2017-09-01 trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos BR112019004189A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383267P 2016-09-02 2016-09-02
US62/383,267 2016-09-02
PCT/US2017/049894 WO2018045308A1 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Publications (1)

Publication Number Publication Date
BR112019004189A2 true BR112019004189A2 (pt) 2019-06-25

Family

ID=59887401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004189-3A BR112019004189A2 (pt) 2016-09-02 2017-09-01 trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos

Country Status (11)

Country Link
US (3) US11338033B2 (https=)
EP (1) EP3506938A1 (https=)
JP (3) JP7183149B2 (https=)
KR (2) KR20190056382A (https=)
CN (2) CN110167585B (https=)
AU (2) AU2017321883B2 (https=)
BR (1) BR112019004189A2 (https=)
CA (1) CA3035443A1 (https=)
IL (3) IL265121B2 (https=)
SG (2) SG10201912944QA (https=)
WO (1) WO2018045308A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
SG10201912944QA (en) * 2016-09-02 2020-02-27 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
CN113423718A (zh) 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
US20240207385A1 (en) * 2020-02-26 2024-06-27 The Wistar Institute Of Anatomy And Biology Compositions comprising self-assembling vaccines and methods of using the same
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
CA3212653A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
CA3222568A1 (en) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
EP4401767A1 (en) * 2021-09-16 2024-07-24 Emergent Product Development Gaithersburg Inc. Vaccine compositions
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
WO2024197134A1 (en) * 2023-03-21 2024-09-26 President And Fellows Of Harvard College Coronavirus spike protein-based vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CA2776391C (en) 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
CN1659187A (zh) 2002-05-10 2005-08-24 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
US7138252B2 (en) * 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
WO2007032241A1 (ja) 2005-09-12 2007-03-22 Japan Science And Technology Agency 微粒子－タンパク質複合体およびその作製方法、半導体装置、蛍光標識方法
EP2111233A2 (en) 2006-12-29 2009-10-28 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
EP2160198A2 (en) 2007-05-31 2010-03-10 Statens Serum Institut Influenza vaccines
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
WO2009026397A2 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
KR101773431B1 (ko) 2009-09-22 2017-09-12 메디카고 인코포레이티드 식물-유래 ｖｌｐ의 제조방법
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
JP2013520167A (ja) 2010-02-18 2013-06-06 テクノヴァックス，インコーポレイテッド 万能ウイルス様粒子（ｖｌｐ）インフルエンザワクチン
AU2011344126B2 (en) * 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP4241785B1 (en) * 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
EP2758038B1 (en) * 2011-09-23 2018-05-30 The United States of America, as represented by The Secretary, Department of Health & Human Services Novel influenza hemagglutinin protein-based vaccines
EP3566714A1 (en) * 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CN104582714A (zh) 2012-05-23 2015-04-29 斯坦福大学托管董事会 流感疫苗构建体
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
EA034639B1 (ru) 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
WO2015054639A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
EP3063273B8 (en) 2013-10-28 2020-12-30 Blue Sky Vaccines GmbH Influenza virus vector for virotherapy
US10363301B2 (en) * 2014-05-27 2019-07-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
EA035375B1 (ru) * 2014-07-10 2020-06-03 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
SG10201912944QA (en) * 2016-09-02 2020-02-27 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza

Also Published As

Publication number Publication date
KR20240042570A (ko) 2024-04-02
JP2023018073A (ja) 2023-02-07
US20220339278A1 (en) 2022-10-27
CA3035443A1 (en) 2018-03-08
IL303650B1 (en) 2024-10-01
AU2022246465A1 (en) 2022-11-17
JP2019537424A (ja) 2019-12-26
JP7500692B2 (ja) 2024-06-17
US11338033B2 (en) 2022-05-24
US20190192651A1 (en) 2019-06-27
WO2018045308A1 (en) 2018-03-08
AU2022246465B2 (en) 2024-05-30
KR20190056382A (ko) 2019-05-24
IL303650A (en) 2023-08-01
CN110167585B (zh) 2024-03-08
EP3506938A1 (en) 2019-07-10
IL315821A (en) 2024-11-01
IL265121B1 (en) 2023-07-01
CN118146389A (zh) 2024-06-07
SG10201912944QA (en) 2020-02-27
AU2017321883B2 (en) 2022-07-07
CN110167585A (zh) 2019-08-23
IL303650B2 (en) 2025-02-01
IL265121A (https=) 2019-04-30
JP2024123036A (ja) 2024-09-10
SG11201901790YA (en) 2019-03-28
US20240050554A1 (en) 2024-02-15
AU2017321883A1 (en) 2019-04-18
US12527857B2 (en) 2026-01-20
IL265121B2 (en) 2023-11-01
US11793871B2 (en) 2023-10-24
JP7183149B2 (ja) 2022-12-05

Similar Documents

Publication Publication Date Title
BR112019004189A2 (pt) trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos
WO2013044203A3 (en) Novel influenza hemagglutinin protein-based vaccines
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
BR112017027448A2 (pt) vacina contra rsv
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
CO2018003863A2 (es) Anticuerpos anti-vegf
BR112017016417A2 (pt) moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
BR112016013138A2 (pt) mistura de peptídeos
BR112015030582A2 (pt) Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
BR112017015833A2 (pt) compostos anti-senescência e usos dos mesmos
BR112016030577A8 (pt) polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
CY1125681T1 (el) Εμβολια κατα του ιου της γριπης και χρησεις αυτων
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
BR112015023738B8 (pt) Vacinas de nucleoproteina influenza
MX2024006290A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
BR112017013574A2 (pt) conjugados de aminoácido e peptídeo e usos dos mesmos
BR112018003580A2 (pt) molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante
BR112017013269A2 (pt) ?composição farmacêutica líquida?

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]